Search
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigationalIt was developed by Novartis and was granted FDA approval on November 15, 2019. … [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug
Diroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigationalDiroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225] … [A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe.
Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigationalCompared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. … in Pompe disease.
Magnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigational[L2831] It is also considered as an active ingredient in over-the-counter products.[L1113] … [T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.
Mixtures: PEN Prep PlusProducts: PEN PrepIndacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Prednicarbate
go.drugbank.com/drugs/DB01130ApprovedIt is used in the treatment of inflammatory skin diseases, such as atopic dermatitis. … It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.
International brands: Dermatop E EmollientBelumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925] … Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension.
Phenindione
go.drugbank.com/drugs/DB00498ApprovedInvestigationalAn indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)
Streptococcus pneumoniae type 5 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10323ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer Fertigspritze